Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance

PFIZER INC

2023-Q3 EPS reported $0.96 revenue$44,247,000,000

Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.
Reported diluted LPS $(0.42); adjusted diluted LPS $(0.17), including $5.6B non-cash inventory write-offs.
Reaffirms FY2023 guidance: revenue $58-61B, adjusted EPS $1.45-$1.65; expects $1B cost savings in 2023.
Comirnaty revenue down 70% operationally; Paxlovid down 97% operationally; Abrysvo contributed $375M.
Launched enterprise cost realignment program targeting at least $3.5B annual net savings by end of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported the third quarter of 2023 results: revenue Revenues of $13.2 Billion, net income Reported (2) Net Income/(Loss) (2,382), EPS Reported (2) Diluted EPS/(LPS) (0.42). Guidance reaffirmed.

Period: the third quarter of 2023
Revenue: Revenues of $13.2 Billion
Net income: Reported (2) Net Income/(Loss) (2,382)
EPS: Reported (2) Diluted EPS/(LPS) (0.42)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports Third-Quarter 2023 Results ▪ Third-Quarter 2023 Revenues of $13.2 Billion – Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues – Revenues for Pfizer’s Non-COVID Products Grew 10%

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-23-000111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.